ASH 2017 | The MUK Seven trial: tackling the issue of R/R multiple myeloma
Martin Kaiser
• 9 Dec 2017
In 2016, 250 patients with relapsed and/or refractory multiple myeloma (MM) were enrolled onto the Myeloma UK (MUK) Seven trial (NCT02406222); a randomized Phase II study that investigated whether the addition of cyclophosphamide to pomalidomide and dexamethasone improved progression-free survival (PFS). Speaking at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Martin Kaiser, MD, of The Royal Marsden Hospital NHS Foundation Trust, London, UK, discusses the systematic approach of the MUK Seven trial and shares his hopes of discovering what factors drive disease relapse.
